Insulin-like growth factor-1 receptor participates in the anti-MDS action involving the MICA/B-NKG2D axis
- 1Department of Hematology, Tianjin Medical University General Hospital
- 2Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control
- 3Tianjin Institute of Hematology
Abstract
Purpose: Myelodysplastic syndromes (MDS) represent a clonal malignancy of the hematopoietic system with a high risk of progression to acute myeloid leukemia (AML). Patients with MDS commonly exhibit natural killer (NK) cell dysfunction, impairing their ability to effectively eliminate malignant cells and posing a serious health threat. The key to treating MDS and preventing its progression to AML lies in restoring and activating NK cell killing functions while eliminating malignant cells, thereby establishing immune interactions between MDS cells and NK cells.
Method: We screened the bone marrow of three patients with primary MDS and three patients with MDS converted to AML for relevant differential genes by Nanostring technology and screened for IGF-1R. We explored the potential and mechanisms of targeting IGF-1R in the treatment of MDS by flow cytometry, immunofluorescence, Western blot, and cell co-culture techniques.
Results: Nanostring sequencing results showed differential expression of IGF-1R in bone marrow cells from MDS patients and trans-AML patients. Differential expression was found to be concentrated on CD34+ cells by flow cytometry. Inhibition of IGF-1R induced DNA damage in MDS cell lines SKM-1 and KG-1, upregulated MICA/B on the surface of MDS cells, and enhanced NK cell-mediated killing of MDS cells, consistent with the involvement of the MICA/B–NKG2D axis.
Conclusion: IGF-1R is involved in the genesis and development of MDS and may modulate the interaction between MDS cells and NK cells, thus serving as a potential target for MDS therapy.
Related
- When Appearances Deceive: A Silent Somatotroph Macroadenoma Presenting With Acromegaloid Features and Paradoxically Low Insulin-Like Growth Factor-1
- Distinct patterns of insulin-like growth factor binding protein (IGFBP)-2 and IGFBP-3 expression in oxidant exposed lung epithelial cells
- Local Administration of Insulin‐Like Growth Factor 1 Attenuates Neuronal Loss and Muscle Atrophy in a Guinea Pig Model of Severe Facial Paralysis
- Concentrated growth factor in combination with insulin for improving type 2 diabetes mellitus alveolar bone regeneration: a pilot study
- Polydeoxyribonucleotide Promotes Longitudinal Bone Growth Through the Hepatic JAK2-STAT5/IGF-1 Axis Involving A2A Receptor Signaling
BibTeX
@article{liu2026insulinlike,
title = {{Insulin-like growth factor-1 receptor participates in the anti-MDS action involving the MICA/B-NKG2D axis}},
author = {Xiaohan Liu and Lei Huang and Yixuan Guo and Juan Mu and Xueke Zhu and Zhaoyun Liu and Rong Fu},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1960550},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1960550/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Insulin-like growth factor-1 receptor participates in the anti-MDS action involving the MICA/B-NKG2D axis
AU - Xiaohan Liu
AU - Lei Huang
AU - Yixuan Guo
AU - Juan Mu
AU - Xueke Zhu
AU - Zhaoyun Liu
AU - Rong Fu
PY - 2026
DA - 2026/10/29
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1960550
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1960550/full
AB - Purpose: Myelodysplastic syndromes (MDS) represent a clonal malignancy of the hematopoietic system with a high risk of progression to acute myeloid leukemia (AML). Patients with MDS commonly exhibit natural killer (NK) cell dysfunction, impairing their ability to effectively eliminate malignant cells and posing a serious health threat. The key to treating MDS and preventing its progression to AML lies in restoring and activating NK cell killing functions while eliminating malignant cells, thereby establishing immune interactions between MDS cells and NK cells. Method: We screened the bone marrow of three patients with primary MDS and three patients with MDS converted to AML for relevant differential genes by Nanostring technology and screened for IGF-1R. We explored the potential and mechanisms of targeting IGF-1R in the treatment of MDS by flow cytometry, immunofluorescence, Western blot, and cell co-culture techniques. Results: Nanostring sequencing results showed differential expression of IGF-1R in bone marrow cells from MDS patients and trans-AML patients. Differential expression was found to be concentrated on CD34+ cells by flow cytometry. Inhibition of IGF-1R induced DNA damage in MDS cell lines SKM-1 and KG-1, upregulated MICA/B on the surface of MDS cells, and enhanced NK cell-mediated killing of MDS cells, consistent with the involvement of the MICA/B–NKG2D axis. Conclusion: IGF-1R is involved in the genesis and development of MDS and may modulate the interaction between MDS cells and NK cells, thus serving as a potential target for MDS therapy.
SN - 2234-943X
ER -